Military Personnel Also Receive Stem Cell Therapy
Military personnel also receive stem cell treatment. Miracell’s Stem Cell ExtractorSelected as a “Public Innovation Product” by the Public Procurement ServicePromoting Supply to Military Hospitals and Other Public Healthcare Services The door is now open for ROK military personnel to receive cutting-edge stem cell treatments developed by a domestic company. Stem cell specialist Miracell announced on the 17th that its “Bone Marrow and Blood Stem Cell Extractor” was selected as a candidate for the Public Sector Evaluation of Innovative Products by the Public Procurement Service on the 18th of last month. To improve the quality of public services, the government operates an innovative product designation system that contracts innovative products at the national level and supports them with public institutions. With this designation, Miracell can now supply stem cell extraction devices through private contracts with public institutions. Miracell CEO Shin Hyun-soon (pictured)“This means we can now supply products certified as new health technologies to public hospitals,” he said. “We are currently coordinating with the Armed Forces Hospital under the Armed Forces Medical Command regarding their adoption.” If Miracell’s stem cell extraction device is approved for delivery to military hospitals, soldiers who suffered trauma during training or suffered chronic pain are expected to benefit. CEO Shin emphasized, “Providing stem cell treatment opportunities to soldiers who have unfortunately retired due to lack of treatment benefits or those who have been hospitalized for long periods of time will contribute to national defense and reduce treatment time and costs.” Miracell plans to gradually expand its services beyond military hospitals to public medical institutions in Korea. Consequently, not only military personnel but also police officers and firefighters will be able to benefit from stem cell treatment. Miracell’s “Smart Mcell 2,” a bone marrow and blood stem cell extraction device, is considered a domestically produced alternative to the “Smart Prep” developed by the Harvard University Immunology Institute. This device extracts bone marrow and blood, concentrates them through centrifugation, and automatically separates stem cells to extract large quantities. It is already in use at major hospitals in Korea, including Soonchunhyang University Hospital. Miracell was recently selected as a “National Representative Innovative Company” by nine ministries, including the Ministry of Trade, Industry and Energy. CEO Shin is using this designation as a springboard for aggressive overseas expansion. He plans to establish a production system by installing automated facilities and expanding factories with government financial support. Miracell has already signed Non-Disclosure Agreements (NDAs) with 13 countries and is currently negotiating the details of these agreements. These include countries within the European Union (EU), the Middle East, and Southeast Asia. CEO Shin stated, “Our long-term goal is to export to 40 countries worldwide. We will actively pursue exports, taking advantage of our product’s superior performance and price competitiveness compared to existing US products.” [Reporter Park Yoon-gyun]